---
layout: default
title: Fluorometholone
parent: 僅模型預測 (L5)
nav_order: 351
evidence_level: L5
indication_count: 10
---

# Fluorometholone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluorometholone: From Non-Infectious Ocular Inflammation to Infectious Anterior Uveitis

## One-Sentence Summary

Fluorometholone is a low-penetration topical corticosteroid already used as standard therapy for non-infectious anterior uveitis and other ocular inflammatory conditions.
The TxGNN model predicts it may also be effective for **Infectious Anterior Uveitis**, but this direction is currently supported by only **1 review article** and **no clinical trials**, and carries a mechanistic caution (steroid monotherapy risks worsening unresolved infection).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in current NPRA licensing data (data gap) — clinically established as a topical corticosteroid for ocular inflammation |
| Predicted New Indication | Infectious Anterior Uveitis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank query pending). Based on known clinical use, fluorometholone is a topical corticosteroid with relatively low corneal/intraocular penetration compared to agents like prednisolone acetate or dexamethasone. It is an established first- or second-line agent for controlling inflammation in **non-infectious** anterior uveitis.

The predicted new indication, **infectious anterior uveitis**, shares the same anatomical site and inflammatory pathway as the drug's established use — corticosteroids suppress the same inflammatory cascade regardless of the infectious or non-infectious trigger. This is the mechanistic basis for the TxGNN association.

However, this relationship requires an important caveat: in infectious anterior uveitis, corticosteroid monotherapy without confirmed control of the underlying pathogen can suppress local immune defenses and worsen the infection. Any repurposing pathway for this indication would need to be framed strictly as **adjunctive anti-inflammatory therapy after or alongside antimicrobial treatment**, not as a standalone therapy — a distinction the evidence pack's own rationale explicitly flags.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [29739028](https://pubmed.ncbi.nlm.nih.gov/29739028/) | 2018 | Review | Klinische Monatsblätter für Augenheilkunde | Reviews topical corticosteroids/NSAIDs for anterior uveitis; notes prednisolone acetate 1% penetrates best, while loteprednol and fluorometholone have comparatively lower intraocular efficacy. Discusses non-infectious uveitis; does not directly address infectious cases. |

---

## Malaysia Market Information

One NPRA registration exists (total_licenses = 1), but the license record contains no product name, dosage form, manufacturer, or approved indication text in the current data — full authorization details need to be pulled directly from the NPRA registry.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug interaction data are all currently unavailable — see DG001 below.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
A Blocking data gap (DG001 — missing NPRA label warnings/contraindications) prevents even an initial safety screen (S1), and the top-ranked indication (infectious anterior uveitis) is supported only by one indirect review article with no clinical trial evidence, plus a real mechanistic safety concern around steroid-only use in unresolved infection.

**To proceed, the following is needed:**
- Package insert / label warnings and contraindications (DG001 — download from NPRA and parse)
- DrugBank mechanism of action data (DG002)
- Consider re-prioritizing evaluation toward rank #4, "post-bacterial disorder" (evidence level L3, active Phase 2 trial NCT07308938 on fluorometholone as adjunct therapy for bacterial corneal ulcers), which has stronger near-term evidence potential than the top-ranked infectious anterior uveitis candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

